Last updated on September 2006

A Dose Study of Doxil in a Dose Dense 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diffuse Large B Cell Lymphoma | Lymphoma | Non-Hodgkin
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    60 years old and older or 18 years old and older with significant/potential cardiac
    morbidity
    Diagnosis of diffuse large B cell lymphoma, Ann Arbor stage I-IV, any International
    Prognostic Index (IPI) score.
    Previously untreated
    New York Heart Association (NYHA) classification of Class III or better
    Baseline ejection fraction (EF) > 25%
    Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3
    Unless attributable to NHL: absolute neutrophil count (ANC) > 1500/uL, platelets >
    100,000/uL; hemoglobin > 9.0 g/dl
    Bilirubin < 1.5 mg/dL (unless related to lymphoma)
    Hepatic: transaminases < 2.5 x upper limit of normal (ULN) (unless related to
    lymphoma)
    Creatinine < 2.5 mg/dl (unless related to lymphoma)

You may not be eligible for this study if the following are true:

  • No HIV+ individuals
    No primary central nervous system (CNS) lymphoma
    No pregnant or lactating women
    No serious active infection
    History of prior malignancy within the last 5 years other than subject's original
    cancer diagnosis listed in inclusion criteria with the exception of curatively
    treated basal cell carcinoma.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.